User 279269

Potential Short Trades on Pending FDA Decisions

I understand you are talking about the group as a whole and you make a fair,argument, but your first mention is that of CYPB in a negative light as the FDA decision "is likely to be delayed until early 2009" casting doubt for investors. That is not consistent with you saying you already wrote a positive article. Also, The potential downside risk for CYPB is just not there and if approved would greatly affect my short position in the ETF of these biotechs in the next few weeks. We already have analysts giving CYPB a 70-80% chance of first approval with no delay.

So, on the whole I'd have to disagree with you on the ETF position as many of these stocks are oversold, are recovering, and have potential upside more than down - CYPB is just one example. This stock should be near 8 or 9 right now.

Potential Short Trades on Pending FDA Decisions

When this stock is valued at $4.10 based on cash holdings alone...
When the initial Phase 3 trials showed a positive response with no side-effects.
When we know that malnicprin already is approved in Europe for years
When we know new data is coming in the next couple months from further Phase 3 trials
When we know the FDA holds a decision that could send the stock soaring
When we know Forrest LAbs is a potential buy-out partner
When we know the stock is trading only $1.50 above its cash value...

Where on earth is the potential short-trade on this stock? From $6 to $5. Are you crazy?

Are you just trying to drive up the short-interest on this stock. We could see $15-20 in 3 weeks...or we might go from $6 to $5....Yeah, I totally see the downside risk.

Idiot.